Search the GHTC website

Global health R&D delivers for Delaware

US government investment in global health R&D has delivered

$28.1 million
to Delaware research institutions
200+ new jobs
for Delaware
Delaware's top USG-funded global health R&D institutions

Delaware's top USG-funded global health R&D institutions

ANP Technologies
$21.3 million
University of Delaware
$6 million
Nemours Children's Hospital, Delaware (formerly Nemours/Alfred I. duPont Hospital for Children)
$408 thousand
$349 thousand

Delaware's top areas of global health R&D by USG funding

Reproductive health
Multi-disease/health area R&D
Global health R&D at work in Delaware

A research lab at the University of Delaware’s College of Engineering is doing pioneering work in the field of synthetic biology, which involves breaking down the components of organisms, such as cells and enzymes, and reassembling them to have new, useful abilities. With support from the US National Institutes of Health, the team is using synthetic biology techniques to design low-cost, shelf-stable oral vaccines by “teaching” benign bacteria to produce an amino acid that would elicit an immune response. Most vaccines available today must be continuously refrigerated to remain effective. This poses a challenge for delivery, particularly in low-resource settings worldwide without reliable electricity. Expanding heat-stable, needle-free vaccine options would help increase the administration and uptake of vaccines both globally and in the United States.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: NIAID